{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:31:50Z","timestamp":1761129110606},"reference-count":22,"publisher":"BMJ","issue":"Suppl 4","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Sex Transm Infect"],"accepted":{"date-parts":[[2013,9,30]]},"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:p>The combination of continually increasing minimum inhibitory concentration values, and outright resistance to the currently available treatments for<jats:italic>Neisseria gonorrhoeae,<\/jats:italic>and the paucity of new drugs in the developmental pipeline raises questions that require concentrated research attention at both the microbiologic and programme levels. Here, we describe the need for research related to the mechanisms of resistance, strategies to reduce or prevent the development of resistance and the need for optimal surveillance using local, national and global data.<\/jats:p>","DOI":"10.1136\/sextrans-2013-051021","type":"journal-article","created":{"date-parts":[[2013,11,15]],"date-time":"2013-11-15T14:33:46Z","timestamp":1384526026000},"page":"iv60-iv62","update-policy":"http:\/\/dx.doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":8,"title":["Evolving gonococcal antimicrobial resistance: research priorities and implications for management"],"prefix":"10.1136","volume":"89","author":[{"given":"Edward W","family":"Hook","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Van Der Pol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2013,11,15]]},"reference":[{"key":"2024051410084074000_89.Suppl_4.iv60.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1112456"},{"key":"2024051410084074000_89.Suppl_4.iv60.2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.044164"},{"key":"2024051410084074000_89.Suppl_4.iv60.3","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-197904000-00017"},{"key":"2024051410084074000_89.Suppl_4.iv60.4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1056\/NEJM197601012940102","article-title":"National gonorrhea therapy monitoring study: in vitro susceptibility and its correlation with treatment results","volume":"294","author":"Jaffe","year":"1976","journal-title":"NEJM"},{"key":"2024051410084074000_89.Suppl_4.iv60.5","doi-asserted-by":"publisher","DOI":"10.1086\/516472"},{"key":"2024051410084074000_89.Suppl_4.iv60.6","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00004"},{"key":"2024051410084074000_89.Suppl_4.iv60.7","doi-asserted-by":"publisher","DOI":"10.1097\/00007435-198304000-00007"},{"key":"2024051410084074000_89.Suppl_4.iv60.8","first-page":"590","article-title":"Update to CDC's sexually transmitted diseases treatment guidelines, 2010; Oral Cephalosporins no longer a recommended treatment for gonococcal infections","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2024051410084074000_89.Suppl_4.iv60.9","unstructured":"Centers for Disease Control and Prevention. Sexually transmitted disease surveillance 2011 . Atlanta: U.S. Department of Health and Human Services, 2012."},{"key":"2024051410084074000_89.Suppl_4.iv60.10","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00325-11"},{"key":"2024051410084074000_89.Suppl_4.iv60.11","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05760-11"},{"key":"2024051410084074000_89.Suppl_4.iv60.12","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/159.5.900"},{"key":"2024051410084074000_89.Suppl_4.iv60.13","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00326-12"},{"key":"2024051410084074000_89.Suppl_4.iv60.14","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00505-12"},{"key":"2024051410084074000_89.Suppl_4.iv60.15","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00729-12"},{"key":"2024051410084074000_89.Suppl_4.iv60.16","doi-asserted-by":"publisher","DOI":"10.3201\/eid1808.111202"},{"key":"2024051410084074000_89.Suppl_4.iv60.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707303170504"},{"key":"2024051410084074000_89.Suppl_4.iv60.18","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-61779-937-2_22"},{"key":"2024051410084074000_89.Suppl_4.iv60.19","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2010.044230"},{"key":"2024051410084074000_89.Suppl_4.iv60.20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1990.03450110059027"},{"key":"2024051410084074000_89.Suppl_4.iv60.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.176575"},{"key":"2024051410084074000_89.Suppl_4.iv60.22","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1128\/AAC.15.4.587","article-title":"Pharmacokinetic determinants of penicillin cure of gonococcal urethritis","volume":"15","author":"Jaffe","year":"1979","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Sexually Transmitted Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/sextrans-2013-051021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T17:09:58Z","timestamp":1715706598000},"score":1,"resource":{"primary":{"URL":"https:\/\/sti.bmj.com\/lookup\/doi\/10.1136\/sextrans-2013-051021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,15]]},"references-count":22,"journal-issue":{"issue":"Suppl 4","published-online":{"date-parts":[[2013,11,15]]},"published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1136\/sextrans-2013-051021"],"URL":"https:\/\/doi.org\/10.1136\/sextrans-2013-051021","relation":{},"ISSN":["1368-4973","1472-3263"],"issn-type":[{"value":"1368-4973","type":"print"},{"value":"1472-3263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,15]]}}}